Advertisement

Inflammatory Bowel Disease in Pregnancy

  • Sunanda Kane

Keywords

Inflammatory Bowel Disease Ulcerative Colitis Breast Milk Pregnancy Outcome Crohn Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8–15.PubMedGoogle Scholar
  2. 2.
    Silverstein MD, Lashner BA, Hanauer SB, Evans AA, Kirsner JB. Cigarette smoking in Crohn disease. Am J Gastroenterol 1989;84:31–3.PubMedGoogle Scholar
  3. 3.
    Suris JC, Resnick MD, Cassuto N, Blum RW. Sexual behavior of adolescents with chronic disease and disability. J Adolesc Health. 1996;19(2):153–6.PubMedGoogle Scholar
  4. 4.
    Newacheck P, Halfon N. Prevalence and impact of disabling chronic conditions in childhood. Am J Public Health.1998;88:610–617PubMedGoogle Scholar
  5. 5.
    Gittes EB, Strickland JL. Contraceptive Choices for Chronically Ill Adolescents. Adolesc Med. 2005;16:635–644.Google Scholar
  6. 6.
    Banks B, Korelitz BI, Zetzel L. The course of non-specific ulcerative colitis: A review of twenty years of experience and late results. Gastroenterol 1957;32:983–1012.Google Scholar
  7. 7.
    Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut1980;21:469–74.PubMedGoogle Scholar
  8. 8.
    Boyko EJ, Theis MK, Vaughan TL, Nicol-Blades B. Increased risk of inflammatory bowel disease associated with oral contraceptive use. Am J Epidemiol 1994;140:268–78.PubMedGoogle Scholar
  9. 9.
    Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and Crohn disease: a community-based matched case-control study. Gastroenterol 1989;97:1442–7.Google Scholar
  10. 10.
    Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and ulcerative colitis. Gastroenterol 1990;99:1032–6.Google Scholar
  11. 11.
    Alic M. Epidemiology supports oral contraceptives as a risk factor in Crohn disease. Gut2000;46:140.PubMedGoogle Scholar
  12. 12.
    Cottone M, Camma, C, Orlando, A, et al. Oral contraceptive and recurrence in crohn disease. Gastroenterol 1999;116:A693.Google Scholar
  13. 13.
    Coley RL, Chase-Lansdale PL. Adolescent pregnancy and parenthood:Recent evidence and future direction. Am Psychol 1998;53:152–166.PubMedGoogle Scholar
  14. 14.
    Woolfson K, Cohen Z, McLeod RS. Crohn disease and pregnancy. Dis Colon Rectum 1990;33:869–73.PubMedGoogle Scholar
  15. 15.
    Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn disease: a case control study by European collaborative group. Gut1986;27:821–5.PubMedGoogle Scholar
  16. 16.
    Fonager K, Sorensen HT, Olsen J, Dahlerup JF, Rasmussen SN. Pregnancy outcome for women with Crohn disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 1998;93:2426–30.PubMedGoogle Scholar
  17. 17.
    Birnie GG, McLeod TI, Watkinson G. Incidence of sulphasalazine-induced male infertility. Gut1981;22:452–5.PubMedGoogle Scholar
  18. 18.
    Burnell D, Mayberry J, Calcraft BJ, Morris JS, Rhodes J. Male fertility in Crohn disease. Postgrad Med J 1986;62:269–72.PubMedGoogle Scholar
  19. 19.
    Dejaco C, Mittemaier C, Reinisch W, et al. Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterol 2001;121:1048–53.Google Scholar
  20. 20.
    Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn disease: a case control study by European collaborative group. Gut1986;27:821–5.PubMedGoogle Scholar
  21. 21.
    Miller JP. Inflammatory bowel disease in pregnancy: a review. J R Soc Med 1986;79:221–5.PubMedGoogle Scholar
  22. 22.
    Moser MA, Okun NB, Mayes DC, Bailey RJ. Crohn disease, pregnancy, and birth weight. Am J Gastroenterol 2000;95:1021–6.PubMedGoogle Scholar
  23. 23.
    Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol 1984;6:211–6.PubMedGoogle Scholar
  24. 24.
    Nielsen O, Andreasson B, Bondesen S, et al. Pregnancy in ulcerative colitis. Scan J Gastroenterol 1983;18:735–42.Google Scholar
  25. 25.
    Kornfeld D, Cnattingius S, Ekbom A. Pregnancy outcomes in women with inflammatory bowel disease–a population-based cohort study. Am J Obstet Gynecol 1997;177:942–6.PubMedGoogle Scholar
  26. 26.
    Schade RR, Van Thiel DH, Gavaler JS. Chronic idiopathic ulcerative colitis. Pregnancy and fetal outcome. Dig Dis Sci 1984;29:614–9.PubMedGoogle Scholar
  27. 27.
    Porter RJ, Stirrat GM. The effects of inflammatory bowel disease on pregnancy:A case- controlled retrospective analysis. Br J Obstet Gynaecol 1986;93:1124–31.PubMedGoogle Scholar
  28. 28.
    Mogadam M, Korelitz BI, Ahmed SW, Dobbins WD, Baiocco PJ. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol 1981;75:265–9.PubMedGoogle Scholar
  29. 29.
    Nielsen O, Andreasson B, Bondesen S, et al. Pregnancy in ulcerative colitis. Scan J Gastroenterol 1983;18:735–42.Google Scholar
  30. 30.
    Levy N, Roisman I, Teodor I. Ulcerative colitis in pregnancy in Israel. Dis Colon Rectum 1981;24:351–4.PubMedGoogle Scholar
  31. 31.
    Kane SV, Hanauer SB, Kiesel J, Shih L, Tyan D. HLA Disparity determines disease activity through pregnancy in Women with IBD. Gastroenterology. 1998;114(4):A1006.Google Scholar
  32. 32.
    Nwokolo C, Tan WC, Andrews HA, Allan RN. Surgical resections in parous patients with distal ileal and colonic Crohn disease. Gut1994;35:220–223.PubMedGoogle Scholar
  33. 33.
    Shoenut JP, Semelka RC, Silverman R, Yaffe CS, Micflikier AB. MRI in the diagnosis of Crohn disease in two pregnant women. J Clin Gastroenterol 1993;17:244–7.PubMedGoogle Scholar
  34. 34.
    Brent RL. The effect of embryonic and fetal exposure to x-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks. Semin Oncol 1989;16:347–68.Google Scholar
  35. 35.
    Cappell MS, Sidhom O. Multicenter, multiyear study of safety and efficacy of flexible sigmoidoscopy during pregnancy in 24 females with follow-up of fetal outcome. Dig Dis Sci 1995;40:472–9.PubMedGoogle Scholar
  36. 36.
    Cappell MS, Colon VJ, Sidhom OA. A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups. Dig Dis Sci 1996;41:2353–61.PubMedGoogle Scholar
  37. 37.
    Sachar D. Exposure to mesalamine during pregnancy increased preterm deliveries (but not birth defects) and decreased birth weight. Gut1998;43:316.PubMedGoogle Scholar
  38. 38.
    Warrell D, Taylor R. Outcome for the foetus of mothers receiving prednisolone during pregnancy. Lancet 1968;1:117–118.PubMedGoogle Scholar
  39. 39.
    Norgard B, Fonager K, Sorensen HT, Olsen J. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. Am J Gastroenterol 2000;95:3165–70.PubMedGoogle Scholar
  40. 40.
    Einarson A, Mastroiacovo P, Arnon J, et al. Prospective, controlled multicenter study of loperamide in pregnancy. Can J Gastroenterol 2000;14:185–87.PubMedGoogle Scholar
  41. 41.
    Bonapace E, Fisher RS. Constipation and diarrhea in pregnancy. Gastroenterol Clin NA 1998;27:197–211.Google Scholar
  42. 42.
    Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003;3:81–92.PubMedGoogle Scholar
  43. 43.
    Loftus EV, JR., Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;19:179–189.PubMedGoogle Scholar
  44. 44.
    Hensleigh PA, Kauffman RE. Maternal absorption and placental transfer of sulfasalazine. Am J Obstet Gynecol. 1977;127:443–444.PubMedGoogle Scholar
  45. 45.
    Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediart Sand 1987;76:137–42.Google Scholar
  46. 46.
    Moody GA, Probert C, Jayanthi V, Mayberry JF. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and female patients with inflammatory bowel disease in Leicestershire. Int J Colorectal Dis 1997;12:220–4.PubMedGoogle Scholar
  47. 47.
    Porter RJ, Stirrat GM. The effects of inflammatory bowel disease on pregnancy: a case- controlled retrospective analysis. Br J Obstet Gynaecol 1986;93:1124–31.PubMedGoogle Scholar
  48. 48.
    Willoughby CP, Truelove SC. Ulcerative colitis and pregnancy. Gut1980;21:469–74.PubMedGoogle Scholar
  49. 49.
    Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin North Am. 2003;32:323–340.PubMedGoogle Scholar
  50. 50.
    Hernandez-Diaz S, Werler MM, Mitchell AA, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608–1614.PubMedGoogle Scholar
  51. 51.
    Ferrero S, Ragni N. Inflammatory bowel disease:management issues during pregnancy. Arch Gynecol Obstet. (2004)270:79–85.PubMedGoogle Scholar
  52. 52.
    Bell CM, Habal FM. Safety of topical 5-aminosalicylic acid in pregnancy. Am J Gastroenterol 1997;92:2201–2.PubMedGoogle Scholar
  53. 53.
    Colombel JF, Brabant G, Gubler MC, et al. Renal insufficiency in infant:side-effect of prenatal exposure to mesalazine?. Lancet 1994;344:620–1.PubMedGoogle Scholar
  54. 54.
    Norgard B, Fonager K, Sorensen HT, et al. Birth outcome in female patients exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut. 2003;52:243–247.PubMedGoogle Scholar
  55. 55.
    Diav-Citrin O, Shechtman S, Ornoy A, et al. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology. 2001;63:186–192.PubMedGoogle Scholar
  56. 56.
    Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol. 1993 ; 82:348–352.PubMedGoogle Scholar
  57. 57.
    Linseman DA, Hampton LA, Branstetter DG. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam Appl Toxicol 1995;28:59–64.PubMedGoogle Scholar
  58. 58.
    Moskovitz DN, Bodian C, Chapman ML, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol. 2004;99:656–661.PubMedGoogle Scholar
  59. 59.
    Loebstein R, Addis A, HO E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother. 1998 ; 42:1336–1339.PubMedGoogle Scholar
  60. 60.
    Einarson A, Mastroacovo P, Arnon J, et al. Prospective, controlled, multicentre study of loperamide in pregnancy. Can J Gastroenterol. 2000;3:185–187.Google Scholar
  61. 61.
    Warrell DW, Taylor R. Outcome for the foetus of mothers receiving prednisolone during pregnancy. Lancet. 1968;1:117–118.PubMedGoogle Scholar
  62. 62.
    Beitins IZ, Bayard F, Migeon CJ, et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr. (1972) 81:936–945.PubMedGoogle Scholar
  63. 63.
    Miller JP. Inflammatory bowel disease in pregnancy:a review. J R Soc Med 1986;79:221–5.PubMedGoogle Scholar
  64. 64.
    Armenti V, Ahlswede KM, Ahlswede RA, et al. National transplant pregnancy registry-outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. 1994 57:502–6.Google Scholar
  65. 65.
    Ramsey-Goldman R SE. Immunosuppressive drug use during pregnancy. Rheum Clin NA 1997;23:149–67.Google Scholar
  66. 66.
    Rosenkrantz JG, Githens JH, Kellum DL, et al. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol. 1967;97:387–394.PubMedGoogle Scholar
  67. 67.
    Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol. 1973;115:1100–1106.PubMedGoogle Scholar
  68. 68.
    Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease:pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2:731–743.PubMedGoogle Scholar
  69. 69.
    Matalon ST, Ornoy A, Lishner M. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs. (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod Toxicol. 2004;18:219–230.PubMedGoogle Scholar
  70. 70.
    Present DH, Meltzer SJ, Korelitz BI, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989 ; 111:641–649.PubMedGoogle Scholar
  71. 71.
    Penn I, Makowski E, Starzl TE, et al. Parenthood in renal homograft recipients. Jama. 1971;216:1755–1761.PubMedGoogle Scholar
  72. 72.
    Gillibrand PN. Systemic lupus erythematosus in pregnancy treated with azathioprine. Proc R Soc Med. 1966;59:834.PubMedGoogle Scholar
  73. 73.
    Norgard B, Pedersen L, Sorensen HT, et al. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther. 2003;17:827–834.PubMedGoogle Scholar
  74. 74.
    Francella A, Dyan A, Present DH, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124:9–17.PubMedGoogle Scholar
  75. 75.
    Goldenberg M, Bider D, Oelsner G, et al. Methotrexate therapy of tubal pregnancy. Hum Reprod. 1993 ; 8:660–666.Google Scholar
  76. 76.
    Srinivasan R. Infliximab treatment and pregnancy outcome in active Crohn disease. Am J Gastroenterol 2001;96:2274–5.PubMedGoogle Scholar
  77. 77.
    Katz JA, Antoni C, Lichenstein GR, et al. Outcome of pregnancy in female patients receiving infliximab for the treatment of Crohn disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385–2392.PubMedGoogle Scholar
  78. 78.
    Tursi A. Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn disease. Dig Liver Dis. 2006;38:439–40.PubMedGoogle Scholar
  79. 79.
    Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin North Am. 2003;32:323–340.PubMedGoogle Scholar
  80. 80.
    Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am. 1997;23:149–167.PubMedGoogle Scholar
  81. 81.
    Bertschinger P, Himmelmann A, Follath F, et al. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol. 1995;90:330.PubMedGoogle Scholar
  82. 82.
    Kornbluth A and Reddy D. Management and outcome of severe colitis in pregnancy. Am J Gastroenterol. 2002;97:P705.Google Scholar
  83. 83.
    Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn disease: an open-label trial. Gastroenterol 1999;117:1271–7.Google Scholar
  84. 84.
    Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn disease. Gastroenterology 1999;117:1278–87.PubMedGoogle Scholar
  85. 85.
    Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn disease: A randomized, double-blind placebo-controlled trial. Gastroenterol 2001;121:1088–94.Google Scholar
  86. 86.
    Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of compicated proximal small bowel and fistulizing Crohn disease. Am J Gastroenterol 1997;92:876–9.PubMedGoogle Scholar
  87. 87.
    Neurath MF, Wanitschke R, Peters M. Randomized trial of mycophenolate versus azathioprine for treatment of chronic active Crohn disease. Gut 1999. 44:625–28.PubMedGoogle Scholar
  88. 88.
    Kainz A, Harabacz I, Cowlrick IS, Gadgil S, Hagiwara D. Analysis of 100 pregnancy outcomes in female patients treated systemically with tacrolimus. Transpl Int 2000;13:S299–300.PubMedGoogle Scholar
  89. 89.
    Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990;88:589–92.PubMedGoogle Scholar
  90. 90.
    Pergola PE, Kancharla A, Riley DJ. Kidney transplantation during the first trimester of pregnancy:immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation 2001;71:994–7.Google Scholar
  91. 91.
    Sills ES, Perloe M, Tucker MJ, Kaplan CR, Palermo GD. Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis. Am J Reprod Immunol 2001;46:366–8.PubMedGoogle Scholar
  92. 92.
    Jacobson L, Clapp, DH. Total parenteral nutrition in pregnancy complicated by Crohn disease. JPEN 1987;11:93–96.Google Scholar
  93. 93.
    Nugent F, Rajala, M, O’Shea, RA, et al. Total parenteral nutrition in pregnancy: conception to delivery. JPEN 1987;11:424–27.Google Scholar
  94. 94.
    Subhani JM, Hamiliton MI. Review article: The management of inflammatory bowel disease during pregnancy. Aliment Pharmacol Ther 1998;12:1039–53.Google Scholar
  95. 95.
    Park YK, Meier ER, Song WO. Characteristics of teenage mothers and predictors of breastfeeding initiation in the Michigan WIC Program in 1995. Women, Infants, and Children. J Hum Lact. 2003;19:50–6.PubMedGoogle Scholar
  96. 96.
    Juhasz ES, Fozard B, Dozois RR, Ilstrup DM, Nelson H. Ileal pouch-anal anastomosis function following childbirth. An extended evaluation. Dis Colon Rectum 1995;38:159–65.PubMedGoogle Scholar
  97. 97.
    Nelis GF. Diarrhoea due to 5-aminosalicyclic acid in breast milk. Lancet 1989;1:383.PubMedGoogle Scholar
  98. 98.
    Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet. 1993;342:618–619.PubMedGoogle Scholar
  99. 99.
    Dubinsky MC. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004;2:731–743.PubMedGoogle Scholar
  100. 100.
    Nyberg G, Haljamae U, Kjemeller I, et al. Breast-feeding during treatment with cyclosporine. Transplantation. 1998;65:253–255.PubMedGoogle Scholar
  101. 101.
    Munoz-Flores-Thiagarajan KD, Easterling T, Bond EF, et al. Breast-feeding by a cyclosporine-treated mother. Obstet Gynecol. 2001;97:816–818.PubMedGoogle Scholar
  102. 102.
    Beitins IZ, Bayard F, Migeon CJ, et al. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr. 1972;81:936–945.PubMedGoogle Scholar
  103. 103.
    Ost L, Wettrell G, Rane A, et al. Prednisolone excretion in human milk. J Pediatr. 1985;106:1008–1011.PubMedGoogle Scholar
  104. 104.
    Kane S. Breastfeeding and IBD: Safety and Management Issues. Inflamm Bowel Dis Monit. 2004;6:50–52.Google Scholar
  105. 105.
    Gibert WM, Jandial D, Field NT, et al. Birth outcomes in teenage pregnancies. J Matern Fetal and Neonatal Med 2004;16:265–270.Google Scholar
  106. 106.
    Ilnyckyj A, Blanchard JF,Rawsthorne P, Bernstein CN. Perianal Crohn Disease and pregnancy:Role of the mode of delivery. Am J Gastroenterol 1999;94:3274–78.Google Scholar
  107. 107.
    Levine W, Diamond B. Surgical procedures during pregnancy. Am J Obstet Gynecol 1961;81:1046–52.PubMedGoogle Scholar
  108. 108.
    Kelly M, Hunt TM, Wicks ACB, et al. Fulminant ulcerative colitis and parturition: a need to alter current management? Br J Obstet Gnecol 1994;101:166–67.Google Scholar
  109. 109.
    Subhani JM, Hamiliton MI. Review article: The management of inflammatory bowel disease during pregnancy. Aliment Pharmacol Ther 1998;12:1039–53.PubMedGoogle Scholar
  110. 110.
    Anderson JB, Turner GM, Williamson RC. Fulminant ulcerative colitis in late pregnancy and the puerperium. J R Soc Med 1987;80:492–4.PubMedGoogle Scholar
  111. 111.
    Boulton R, Hamilton M, Lewis A, Walker P, Pounder R. Fulminant ulcerative colitis in pregnancy. Am J Gastroenterol 1994;89:931–3.PubMedGoogle Scholar
  112. 112.
    Greenfield C, Pounder RE, Craft IL, Lewis AA. Severe ulcerative colitis during successful pregnancy. Postgrad Med J 1983;59:459–61.PubMedGoogle Scholar
  113. 113.
    Hill J, Clark A, Scott NA. Surgical treatment of acute manifestations of Crohn disease during pregnancy. J R Soc Med 1997;90:64–6.PubMedGoogle Scholar
  114. 114.
    Metcalf A, Dozois RR, Baert RW, et al. Pregnancy following ileal pouch-anal anastomosis. Dis Colon Rectum 1985;28:859–61.PubMedGoogle Scholar
  115. 115.
    Olsen KO JS, Berndtsson I, Oresland T, Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterol 2002;122:15–19.Google Scholar
  116. 116.
    Juhasz ES, Fozard B, Dozois RR, Ilstrup DM, Nelson H. Ileal pouch-anal anastomosis function following childbirth. An extended evaluation. Dis Colon Rectum 1995;38:159–65.Google Scholar
  117. 117.
    Baldassano R, Ferry G, Griffiths, A. Transition of the patient With Inflammatory Bowel Disease from pediatric to adult care:Recommendations of the North American society for pediatric gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2002;34:245–248.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Sunanda Kane
    • 1
  1. 1.Mayo ClinicRochesterUSA

Personalised recommendations